Literature DB >> 15766527

RAS is regulated by the let-7 microRNA family.

Steven M Johnson1, Helge Grosshans, Jaclyn Shingara, Mike Byrom, Rich Jarvis, Angie Cheng, Emmanuel Labourier, Kristy L Reinert, David Brown, Frank J Slack.   

Abstract

MicroRNAs (miRNAs) are regulatory RNAs found in multicellular eukaryotes, including humans, where they are implicated in cancer. The let-7 miRNA times seam cell terminal differentiation in C. elegans. Here we show that the let-7 family negatively regulates let-60/RAS. Loss of let-60/RAS suppresses let-7, and the let-60/RAS 3'UTR contains multiple let-7 complementary sites (LCSs), restricting reporter gene expression in a let-7-dependent manner. mir-84, a let-7 family member, is largely absent in vulval precursor cell P6.p at the time that let-60/RAS specifies the 1 degrees vulval fate in that cell, and mir-84 overexpression suppresses the multivulva phenotype of activating let-60/RAS mutations. The 3'UTRs of the human RAS genes contain multiple LCSs, allowing let-7 to regulate RAS expression. let-7 expression is lower in lung tumors than in normal lung tissue, while RAS protein is significantly higher in lung tumors, providing a possible mechanism for let-7 in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766527     DOI: 10.1016/j.cell.2005.01.014

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  1430 in total

1.  Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.

Authors:  Moubin Lin; Jian Gu; Cathy Eng; Lee M Ellis; Michelle A Hildebrandt; Jie Lin; Maosheng Huang; George A Calin; Dingzhi Wang; Raymond N Dubois; Ernest T Hawk; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2012-06-01       Impact factor: 12.531

Review 2.  microRNAs, the cell's Nepenthe: clearing the past during the maternal-to-zygotic transition and cellular reprogramming.

Authors:  Antonio J Giraldez
Journal:  Curr Opin Genet Dev       Date:  2010-05-06       Impact factor: 5.578

Review 3.  Post-transcriptional regulation in metabolic diseases.

Authors:  Wook Kim; Eun Kyung Lee
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

4.  Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia.

Authors:  Suman Bhatia; Deepak Kaul; Neelam Varma
Journal:  Mol Cell Biochem       Date:  2010-10-06       Impact factor: 3.396

Review 5.  Developing therapeutic microRNAs for cancer.

Authors:  A G Bader; D Brown; J Stoudemire; P Lammers
Journal:  Gene Ther       Date:  2011-06-02       Impact factor: 5.250

Review 6.  From microRNAs to targets: pathway discovery in cell fate transitions.

Authors:  Deepa Subramanyam; Robert Blelloch
Journal:  Curr Opin Genet Dev       Date:  2011-06-01       Impact factor: 5.578

7.  Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues.

Authors:  Tram K Lam; Stephanie Shao; Yingdong Zhao; Francesco Marincola; Angela Pesatori; Pier Alberto Bertazzi; Neil E Caporaso; Ena Wang; Maria Teresa Landi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

8.  Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells.

Authors:  Yun Lu; J Michael Thomson; Ho Yuen Frank Wong; Scott M Hammond; Brigid L M Hogan
Journal:  Dev Biol       Date:  2007-08-09       Impact factor: 3.582

9.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

10.  Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.

Authors:  Geoffrey Childs; Melissa Fazzari; Gloria Kung; Nicole Kawachi; Margaret Brandwein-Gensler; Michael McLemore; Quan Chen; Robert D Burk; Richard V Smith; Michael B Prystowsky; Thomas J Belbin; Nicolas F Schlecht
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.